ADMS News and Press, Adamas Pharmaceuticals Inc. From 01/07/19

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect ...

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS...

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more ...

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more ...

Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more...

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto – Director-Investor Relations and Corporate Communications Greg Went – Chairman and Chief Executive Officer Alf Merriweather – Chief F...

Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$1.22 beats by $0.12 . Revenue of $10.6M beats by $0.46M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical compan...

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp. (NASD...